Contravisory Investment Management Inc. lowered its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 10.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,241 shares of the biopharmaceutical company’s stock after selling 272 shares during the period. Contravisory Investment Management Inc.’s holdings in Alexion Pharmaceuticals were worth $350,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ALXN. Glassman Wealth Services increased its holdings in Alexion Pharmaceuticals by 76.0% during the 3rd quarter. Glassman Wealth Services now owns 227 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 98 shares during the period. Evolution Wealth Advisors LLC increased its holdings in Alexion Pharmaceuticals by 766.7% during the 3rd quarter. Evolution Wealth Advisors LLC now owns 260 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 230 shares during the period. Eudaimonia Partners LLC increased its holdings in Alexion Pharmaceuticals by 37.1% during the 3rd quarter. Eudaimonia Partners LLC now owns 288 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 78 shares during the period. Jeppson Wealth Management LLC bought a new stake in Alexion Pharmaceuticals during the 3rd quarter worth approximately $35,000. Finally, Ellevest Inc. grew its stake in Alexion Pharmaceuticals by 165.4% in the 3rd quarter. Ellevest Inc. now owns 337 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 210 shares in the last quarter. 87.27% of the stock is currently owned by institutional investors.

ALXN stock opened at $156.44 on Thursday. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $72.67 and a fifty-two week high of $160.03. The business’s 50 day moving average price is $142.73 and its two-hundred day moving average price is $120.45. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.26 and a current ratio of 3.81. The company has a market capitalization of $34.24 billion, a price-to-earnings ratio of 36.55, a price-to-earnings-growth ratio of 0.76 and a beta of 1.33.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $3.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.64. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.43 billion. Alexion Pharmaceuticals had a return on equity of 23.16% and a net margin of 16.32%. The business’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.79 EPS. Sell-side analysts forecast that Alexion Pharmaceuticals, Inc. will post 11.14 earnings per share for the current year.

A number of research firms have commented on ALXN. Svb Leerink cut their price target on shares of Alexion Pharmaceuticals from $163.00 to $159.00 and set an “outperform” rating for the company in a research note on Friday, October 30th. Morgan Stanley cut their price target on shares of Alexion Pharmaceuticals from $121.00 to $119.00 and set an “equal weight” rating for the company in a research note on Friday, October 30th. Sanford C. Bernstein began coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, November 19th. They issued a “market perform” rating and a $148.00 price target for the company. UBS Group began coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, October 28th. They issued a “neutral” rating and a $133.00 price target for the company. Finally, TheStreet raised shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a sell rating, eighteen have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $151.26.

In related news, CAO Daniel Bazarko sold 24,066 shares of the company’s stock in a transaction that occurred on Thursday, December 17th. The stock was sold at an average price of $157.70, for a total value of $3,795,208.20. Following the sale, the chief accounting officer now owns 43,949 shares in the company, valued at approximately $6,930,757.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Tanisha Carino sold 1,530 shares of the company’s stock in a transaction that occurred on Thursday, December 3rd. The stock was sold at an average price of $122.26, for a total value of $187,057.80. Following the completion of the sale, the chief accounting officer now owns 17,632 shares in the company, valued at approximately $2,155,688.32. The disclosure for this sale can be found here. Corporate insiders own 4.03% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

Featured Story: Average Daily Trade Volume – What You Need to Know

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.